South Korea's Hanmi Pharma out-licensed global rights for its pan-RAF inhibitor to Genentech in an $910 million deal; Ramsay Sime Darby Healthcare, a Malaysian-Australian hospital operator, is close to forming a $500 million China hospital JV; Neusoft, a China IT company, established a $250 million medical device investment fund with Infinity Group of Israel; Shanghai Fosun Pharma and US-based Intuitive Surgical formed a $100 million China medical device JV; MicuRx Pharma, a San Francisco-Shanghai antibiotics company, closed a $55 million Series C financing from China investors; ReadCoor, a next generation sequencing spin-out from Harvard University, raised $23 million in a Series A round from China healthcare investors; Huapont Life Sciences of Chongqing in-licensed China rights to a stem cell-based hair regrowth product developed by San Diego's Histogen; Zai Lab of Shanghai acquired China rights to an oral PARP inhibitor from Boston-based TESARO; China BioPharma Capital, a Chongqing Lummy Pharma investment fund, led a Series C financing in Quantapore, a Bay Area sequencing device company; Shijiazhuang Huanzhong Biotech will assemble and market a new women's fertility product in China developed by Concepta of the UK; Predicine, a Bay Area precision medicine organization, opened a major R&D facility in Shanghai offering liquid- and tissue biopsy diagnostic services; SciClone Pharma of the US advanced the China-Asia clinical trials for two of its products; and CANbridge Life Sciences of Beijing dosed the first patient in a Taiwan Phase I/II trial of its brain cancer treatment.
